Innovators: SPC waiver may drive investment in secondary patents
UCB, GSK and other innovator drug firms explain how the EU’s SPC Manufacturing Waiver might drive larger investments in secondary patent fortresses for new products and strain resources on monitoring and litigation as they seek to interpret the legislation. Read more ...
EU vote on Wi-Fi for driverless cars is disastrous for licensing budgets, say in-house counsel
Telecoms and automotive firms say that proposed EU legislation to adopt Wi-Fi as the standard for driverless cars will force automotive makers to use an outdated technology and put them at a competitive disadvantage to the rest of the world. Read more ...
UK Actavis ruling raises clarity on dosage regimen patents, say drug companies
Medicine access pressure raises injunction considerations for innovators
As governments face growing concern over rising drug prices, in-house counsel from innovator and generic pharmaceutical companies re-examine their strategies when it comes to injunctions. Read more ...
Money
Prosecution highway drives filing efficiencies but hinders claim flexibility
The Patent Prosecution Highway is gaining popularity because of its cost-saving benefits, but it is not always the right tool for the job, according to in-house counsel. Read more ...
